Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation

Keyphrases

• Prostate Cancer 100%
• Cancer Therapeutics 100%
• Differential Effects 100%
• Neuroendocrine Differentiation 100%
• Androgen Receptor Expression 80%
• Androgen Receptor 40%
• Androgen Signaling 40%
• Tumor 20%
• Geldanamycin 20%
• Small Interfering RNA (siRNA) 20%
• Signaling Axis 20%
• Tumor Progression 20%
• Small Molecules 20%
• Cellular Models 20%
• Ablation 20%
• Prostate Cancer Cells 20%
• Histone Deacetylase Inhibitor (HDACi) 20%
• Hormone Refractory 20%
• Advanced Prostate Cancer 20%
• RNA-based 20%
• Cancer Growth 20%
• Androgen Ablation Therapy 20%
• Pharmacologic Agents 20%
• Intervention Strategies 20%
• Therapeutic Importance 20%
• Hsp90 Inhibitor 20%
• Antiandrogen 20%
• Cellular Morphology 20%
• Drug-resistant Cancer 20%
• Neuroendocrine Markers 20%
• Relative Effect 20%
• Neuroendocrine Phenotype 20%
• Androgen Receptor Antagonist 20%
• Transdifferentiation 20%
• Refractory States 20%
• Phenotypic Response 20%

Medicine and Dentistry

• Prostate Cancer 100%
• Androgen Receptor 100%
• Cell Transdifferentiation 100%
• Receptor Expression 50%
• Neuroendocrine Differentiation 37%
• Diseases 12%
• Cancer 12%
• Tumor Progression 12%
• Cancer Growth 12%
• Androgen 12%
• Cancer Cell 12%
• Ablation Therapy 12%
• Histone Deacetylase Inhibitor 12%
• Small Interfering RNA 12%
• Hsp90 Inhibitor 12%
• Cellular Model 12%
• Antiandrogen 12%
• Androgen Receptor Antagonist 12%
• Geldanamycin 12%
• Tumor 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Androgen Receptor 100%
• Diseases 12%
• Cancer Growth 12%
• Tumor Growth 12%
• Androgen 12%
• Histone Deacetylase Inhibitor 12%
• Small Interfering RNA 12%
• Heat Shock Protein 90 Inhibitor 12%
• Geldanamycin 12%
• Antiandrogen 12%
• Androgen Receptor Antagonist 12%